Harmony delivered Q4 2025 net product revenue of 243776000, representing 21% year-over-year growth for WAKIX, with GAAP net income of 22486000 and continued expansion in patients on therapy.

Harmony Biosciences reported strong year-over-year revenue growth for WAKIX® of 20% in the first quarter 2025, building on four consecutive years of profitability, and increased cash and investments to over $600 million on the balance sheet.

Harmony Biosciences reported a record $201.3 million in net product revenues for the fourth quarter of 2024. GAAP net income for the quarter was $49.5 million, or $0.85 earnings per diluted share. The company ended the year with $576 million in cash, cash equivalents and investments.

Harmony Biosciences reported a record $186.0 million in net revenue for Q3 2024. The company is on track to submit an sNDA for pitolisant in Idiopathic Hypersomnia in Q4 2024. They reiterated their 2024 net product revenue guidance of $700 - $720 million.

Harmony Biosciences reported a strong second quarter in 2024, with WAKIX net revenue reaching $172.8 million, a 29% increase year-over-year. The company is advancing its pitolisant high-dose development program and expects a PDUFA date in 2028. They are also on track to submit a supplemental new drug application for pitolisant in Idiopathic Hypersomnia in the fourth quarter of 2024 and reiterated their 2024 net product revenue guidance of $700 - $720 million.

Harmony Biosciences reported a 30% year-over-year net revenue growth for the first quarter of 2024, driven by strong commercial sales of WAKIX. The company is also advancing its pipeline and diversifying its portfolio through strategic business development, including the acquisition of Epygenix Therapeutics, Inc.

Harmony Biosciences reported a strong Q4 2023, with net product revenue of $168.4 million, a 31% increase compared to the same period in 2022. GAAP net income was $26.6 million, or $0.45 per diluted share, while Non-GAAP adjusted net income was $42.8 million, or $0.73 per diluted share. The company is projecting net product revenue between $700 and $720 million for 2024.

Harmony Biosciences reported a strong Q3 2023, with net product revenues reaching $160.3 million, a 37% increase compared to the same period in 2022. The company also expanded its pipeline through the acquisition of Zynerba Pharmaceuticals and initiated a new $200 million share repurchase program.

Harmony Biosciences reported strong second-quarter results, driven by increased demand for WAKIX. Net product revenues reached $134.2 million, a 25% increase compared to the same period in 2022. The company is also making progress in its life cycle management programs, with several catalysts expected in the remainder of the year.

Harmony Biosciences reported a strong first quarter in 2023, marked by a 40% year-over-year increase in WAKIX net revenue, reaching $119.1 million. The company also saw growth in GAAP net income, which rose to $29.5 million, and made progress in its clinical development programs.

Harmony Biosciences reported a strong Q4 2022, with net product revenues reaching $128.3 million, a 40.7% increase compared to the same period in 2021. GAAP net income for the quarter was $48.5 million, or $0.79 per diluted share, while non-GAAP adjusted net income was $61.9 million, or $1.01 per diluted share.

Harmony Biosciences reported a strong third quarter with net product revenues of $117.2 million, a 45.2% increase compared to the same period in 2021. GAAP net income was $87.9 million, or $1.44 per diluted share, compared to a GAAP net loss of $9.6 million, or ($0.17) per diluted share, for the same period in 2021. The company is encouraged by positive data from the PWS Phase 2 study and progress in clinical programs.

Harmony Biosciences reported net product revenues of $107.0 million for the quarter ended June 30, 2022, a 45% increase compared to the same period in 2021. GAAP net income was $23.5 million, or $0.39 per diluted share, while non-GAAP adjusted net income was $34.7 million, or $0.57 per diluted share. The company also signed a new agreement with Bioprojet to develop innovative therapeutics based on pitolisant.

Harmony Biosciences reported a strong first quarter in 2022, with WAKIX net revenue reaching $85.3 million, a 43% increase compared to the same period in 2021, and GAAP net income of $21.5 million, or $0.35 per diluted share.

Harmony Biosciences reported a strong fourth quarter, with WAKIX net revenue increasing by 62% year-over-year to $91.2 million and achieving a net income of $22.7 million.

Harmony Biosciences reported net product revenues of $80.7 million for the quarter ended September 30, 2021, a 77% increase compared to the same period in 2020. GAAP net loss available to shareholders was $9.6 million, or a loss of $0.17 per diluted share, while non-GAAP adjusted net income was $30.4 million, or $0.51 per diluted share.

Harmony Biosciences reported a strong second quarter in 2021, marked by significant revenue growth from WAKIX, strategic progress in clinical development, and a new financing collaboration with Blackstone.